Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 9.14 -0.07 (0.76%)
Day High: 9.29
Day Low:  9.00
Volume:    59,256
1:01 PM ET
01.17.18

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations